Recent Updates
Recently added Catalysts
PFE Positive Sentiment

BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BenchSci has appointed Dr. Mikael Dolsten as its first Chairman of the Board, effective June 2026. Dr. Dolsten, who previously served as Chief Scientific Officer at Pfizer, joined the board as a director in July 2025. His extensive experience in biopharma research is expected to guide BenchSci's future developments.
Price reaction · baseline $24.05 (2026-07-08 close) · hit pre-market · clean, no other PFE news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a highly experienced leader in Dr. Dolsten.
  • First Chairman role in BenchSci's history indicates growth.
  • Dr. Dolsten's background in R&D will enhance strategic direction.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
Exubera
Phase 3 · Diabetes Mellitus

Full Press Release Details

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. Dr. Dolsten joined BenchSci's board as a director in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development, where he could have taken a board seat at ne

Frequently Asked Questions

Who is Dr. Mikael Dolsten?

Dr. Mikael Dolsten is the former Chief Scientific Officer at Pfizer.

When will Dr. Dolsten become Chairman of BenchSci?

He will officially take on the role in June 2026.

What is significant about this appointment?

It marks the first Chairman role in BenchSci's history.

When did Dr. Dolsten join BenchSci's board?

He joined as a director in July 2025.

ShareAdd on Google
Tags: PFE Viatris Investor Conferences Healthcare BenchSci Mikael Dolsten Pfizer biopharma leadership
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$8257M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ExuberaPhase 3
Diabetes Mellitus →

Catalyst track record

+6%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →